CoChat

The Metabolic Syndrome and Aging

Morley, J. E. · 2004 · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
Cited by 92

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

In 1966, Camus first described the concept of the metabolic syndrome (1). From 1988 onwards, the importance of the metabolic syndrome was popularized by Reaven (2). The metabolic syndrome consists of a deadly quintet of factors, namely diabetes, hypertension, hyperuricemia, lipid abnormalities, and alterations in thrombotic potential, that are associated with hyperinsulinemia and insulin resistance. The metabolic syndrome is directly related to increased atherogenesis and death from myocardial infarction. The metabolic syndrome is directly related to the accumulation of visceral adiposity in middle age associated with overeating and a decline in exercise. In addition, there appears to be a genetic predisposition to developing the metabolic syndrome. The metabolic syndrome could be conceived as the “couch potato” syndrome (Figure 1)! It has been estimated that 15% to 20% of persons aged over 70 years have the metabolic syndrome. Banks and colleagues (3) studied a subset of wild baboons (Papio cynocephalus) that foraged from a trash heap in the Kenyan savannah. Some of this tribe of baboons developed hyperleptinemia, hyperinsulinemia, hyperglycemia, elevated insulin/glucose ratios, and increased cholesterol. Others in the same tribe developed hypercholesterolemia but none of the signs of insulin resistance. This demonstrated the importance of the interaction of genetic predisposition with the environment in the pathogenesis of the metabolic syndrome. Besides insulin, two other hormones have been associated with the development of the metabolic syndrome. These are leptin and adiponectin. Both are peptide hormones produced from adipose tissue. Leptin levels closely follow the amount of total adiposity (4,5). Leptin produces anorexia and increased metabolism, thus attempting to decrease the increased adiposity (6). Testosterone decreases leptin levels in males and leads to a decline in body fat (7,8). Thus, the age-related decline in testosterone in males may play a role in the pathogenesis of the metabolic syndrome (9). With increasing obesity, resistance to the effects of leptin occurs. This resistance appears to be due to hypertriglyceridemia. Adiponectin has been shown to enhance insulin sensitivity and decrease triglycerides (10). Low levels of adiponectin are closely associated with the development of insulin resistance. Trunkal fat is associated with increased cytokines such as interleukin-6 and tumor-necrosis factor α (11). These two cytokines play a role in the development of insulin resistance. Testosterone inhibits the production of interleukin-6, again supporting a minor role for the andropause in the development of the metabolic syndrome (12). Numerous recent studies have shown that hypertension is especially lethal in diabetics. Both the SHEP (Systolic Hypertension in Elderly Persons) and the Syst-Eur Trial found an almost doubling of mortality risks in older diabetics with systolic hypertension (13,14). The UKPDS (United Kingdom Prospective Diabetes Study) found that treating blood pressure produced better risk reduction than did treating diabetes (15). In the HOPE (Heart Outcomes and Prevention Evaluation) and CAPP (Captopril Prevention Project) trials, angiotensin-converting enzyme inhibitors had a better effect on lowering cardiovascular events in diabetics compared with nondiabetics (16,17). In addition, in the SCOPE (Study on Cognition and Prognosis in the Elderly) trial angiotensin receptor blockers decreased new onset diabetes by 20% (18). Coronary artery disease can be characterized as the diabetic's sword of Damocles. It is clear that diabetics require aggressive treatment to prevent atherosclerosis. The DIGAMI (diabetes mellitus, insulin glucose infusion in acute myocardial infarction) studies examined 620 persons with diabetes who developed a myocardial infarction (19). The mean age was 68 years. They provided intensive glucose-lowering therapy in all participants with a glucose equal or greater than 11 mmol/L. In a 3.4 year follow-up, they found a reduction in mortality, with only 9 persons being the number needed to treat to prevent 1 additional death. In this issue of the Journals, Rasgon and Jarvik (20) suggest that dementia and depression should be considered, in some cases, to be due to the metabolic syndrome. A number of commentators have taken issue with some of their hypothesis while agreeing with other components (21–24). Recently, in-depth reviews of the pathogenesis of dementia and its associated behaviors (25–27), as well as of depression (28), have appeared in the Journals. The causes of cognitive decline in diabetes are complex and multifactorial. It is clear that diabetes in older persons is associated with a worse cognitive function compared with those who have normal cognition (29,30). Gregg and colleagues (31) followed 682 women aged 72 years with diabetes and found a two-fold increase in cognitive impairment over this period. Numerous studies have shown that not only

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/gerona/59.2.m139

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 92

Metadata

Authors
Morley, J. E.
Venue
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
Published
2004-02-01
Volume
59
Issue
2
Pages
M139-M142
ISSN
  • 1079-5006 (ISSN-L)
  • 1758-535X
OpenAlex
W2112629405
Cited by
92
References
9
FWCI
3.24
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Metabolic Syndrome and Aging. https://app.cochat.ai/papers/10.1093/gerona/59.2.m139
The paper
Morley, J. E. (2004). The Metabolic Syndrome and Aging. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. https://doi.org/10.1093/gerona/59.2.m139

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.